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Pharmacokinetics and Pharmacodynamics of Oral P2Y12 
Inhibitors During the Acute Phase of a Myocardial Infarction: 
A Systematic Review. 
 
Abstract 
Background: The immediate administration of oral antiplatelet therapy in the 
form of aspirin plus a P2Y12 inhibitor is the universally recognised standard of 
care for patients who present with acute myocardial infarction.  Despite strong 
recommendations for their use, there are a paucity of data describing their 
onset of action and clinical efficacy during the short time frames from 
confirmation of diagnosis to reperfusion with primary percutaneous coronary 
intervention. 
Objectives: To complete a systematic review evaluating the currently available 
evidence regarding the pharmacokinetic and pharmacodynamic activity of 
orally administered clopidogrel, prasugrel and ticagrelor during the acute 
phase of a myocardial infarction in relation to mechanical reperfusion with 
primary percutaneous coronary angioplasty. 
Methods: We searched Pubmed and EMBASE databases up to January 2016 
using the terms outlined in our search strategy. 
Results: Twelve papers were included in our final analysis; seven relating to 
pharmacodynamic studies, one to a pharmacokinetic study and four to a 
pharmacokinetic/pharmacodynamic study. 
Conclusion:  Our results indicate that despite the administration of oral P2Y12 
inhibitors including newer more potent agents that should allow for greater 
and more consistent levels of platelet inhibition, the physiological state of ST 
Manuscript
 2 
segment elevation MI (STEMI) and the co-administration of opioid based 
analgesia are associated with a reduction in the degree of platelet inhibition 
achieved following their administration. 
 
 
Keywords 
P2Y12 inhibitors, primary percutaneous coronary intervention, ST elevation 
myocardial infarction, inhibition of platelet activity (IPA), platelet function 
assays, STEMI, aspirin, clopidogrel, ticagrelor, prasugrel 
 
Introduction 
 
Despite significant advances in both the interventional and pharmacological 
management of patients who present with STEMI, there remains significant 
morbidity, mortality and a sizable pharmacoeconomic burden associated with 
the condition (1).  2014 British Heart Foundation statistics data indicate that in 
the United Kingdom alone, 2.3 million people have a current diagnosis of 
coronary heart disease, with approximately 11% of men and 15% of women 
admitted to hospital following a myocardial infarction dying within 30 days of 
presentation (2). 
 
Of all the acute coronary syndromes, STEMI patients suffer the highest early 
mortality and therefore urgent reperfusion and early pharmacological 
intervention are advised and mandated (3). 
 
The principal aim of treatment, following diagnosis of STEMI is to ensure 
timely, rapid and complete restoration of blood flow to the affected part of the 
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myocardium to minimise myocardial cell death and preserve myocardial 
function (4).  Whilst thrombolysis can be considered an option to allow for 
early reperfusion, the likelihood of achieving vessel patency is as low as 50% 
even with the most efficacious agents. Also the increased risk of early 
reinfarction following its administration is associated with adverse outcomes 
and increased mortality (5).   PPCI achieves infarct vessel patency in over 
90% cases and unequivocally improves outcomes in the majority of patients 
when compared to thrombolysis. (6).  
 
Pathophysiology of Myocardial Infarction 
 
The pathophysiology of STEMI in the vast majority of cases relates to the 
rupture of a vulnerable atherothrombotic plaque, with subsequent platelet 
activation and adhesion leading to complex thrombus formation with activation 
of the clotting cascade and abrupt vessel occlusion (7-9).  Although 
mechanical reperfusion via PCI is a highly effective procedure allowing for 
rapid restoration of coronary blood flow to the affected section of the 
myocardium, the administration of adjunctive antithrombotic drug therapies is 
necessary to mitigate against both peri-procedural and post-procedural 
ischaemic and thrombotic complications.  
 
Current Antiplatelet Treatment Options  
 
Since platelets play such a critical role in the underlying disease process and 
associated complications of a myocardial infarction, the recommended 
standard of care following a diagnosis of STEMI is for the immediate 
administration of dual antiplatelet therapy with aspirin plus a second 
antiplatelet agent belonging to the P2Y12 inhibitor class, to prevent further 
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adverse cardiovascular and cerebrovascular events (MACCE) and stent 
thrombosis (10, 11). 
 
 
Aspirin, the most commonly prescribed antiplatelet agent in clinical practice, 
leads to a 23% reduction in mortality in the context of an acute myocardial 
infarction and a 25% reduction in MACCE (12, 13).  However, despite these 
proven benefits, aspirin monotherapy in the context of STEMI and subsequent 
coronary artery stent implantation is insufficient to protect against 
complications such as stent thrombosis, a potentially fatal complication, 
occurring in up to 3% of PPCI cases that is associated with a mortality of 40% 
(14-16).  
 
The armamentarium of antiplatelet therapies and in particular the oral P2Y12 
inhibitors have evolved considerably over the last decade. Clopidogrel, a 
second generation thienopyridine, is an effective orally administered P2Y12 
inhibitor that is supported by an evidence base that spans not only decades 
but also the entire spectrum of acute coronary syndromes, from medically 
managed patients to those who undergo PPCI.  It is, however, subject to a 
number of limitations, which hamper its use in clinical practice.  Firstly, it is a 
pro-drug that requires metabolic conversion to its active form; which occurs 
following a two-step biotransformation process dependent on the cytochrome 
P450 3A4 and 2C19 enzymes (17, 18).  There is significant heterogeneity 
within the general population with regards to the activity of the C19 allele, 
which in turn can lead to impaired conversion of clopidogrel to its active form 
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(18).  These genetic polymorphisms lead to significant inter-individual 
variability in response to its administration; those patients in whom effective 
conversion of clopidogrel to its active form does not take place are at 
increased risk of further thrombotic events (14, 18).  In addition, clopidogrel is 
relatively slow in terms of its onset of action and ability to effectively inhibit 
platelet activity (19, 20).  This is a potential major disadvantage in the context 
of PPCI, where effective and optimal levels of platelet inhibition are required 
almost immediately. 
 
In comparison to clopidogrel, both prasugrel and ticagrelor have 
demonstrated less inter-individual variability in response and are more rapid in 
onset of action providing greater and more consistent levels of platelet 
inhibition (21, 22).  The enhanced pharmacodynamic profile of prasugrel and 
ticagrelor translates into improved clinical efficacy and outcomes with a 
reduction in MACCE and stent thrombosis when compared to clopidogrel as 
demonstrated by the findings of the pivotal TRITON-TIMI 38 (for prasugrel in 
ACS patients undergoing PCI) and PLATO trial (for ticagrelor in patients with 
ACS undergoing both medical and interventional treatment) (23, 24). 
 
Rapid, and effective inhibition of platelet activity is highly desirable and of 
paramount clinical importance in the context of STEMI managed with PPCI 
since the time scales involved from symptom onset to the restoration of blood 
flow are very short; with UK recommendations stipulating a time frame of 120 
minutes from call to balloon time and 90 minutes from arrival to a PPCI 
capable centre to myocardial reperfusion/angioplasty (door to balloon time) to 
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ensure maximal myocardial salvage, preservation of left ventricular function, 
improved outcomes and survival (4) (25, 26).   
 
Following the administration of an oral loading dose, the pharmacodynamic 
data supporting the speed of onset of prasugrel and ticagrelor indicates that 
optimal levels of platelet inhibition are achieved within 30 and 60 minutes 
respectively, however, these data are derived from healthy volunteers or 
patients with stable coronary artery disease and as such is not reflective of 
the physiological state of STEMI in which drug handling is invariably altered 
(21, 22, 27).   
 
Although dual antiplatelet therapy with aspirin and either clopidogrel, 
prasugrel or ticagrelor in the management of acute coronary syndromes is 
supported by an evolving evidence base, there is a lack of pharmacodynamic 
and pharmacokinetic data regarding the efficacy of orally administered P2Y12 
inhibitors during the acute phase of a myocardial infarction.  In view of the 
short times scales involved in PPCI and the physiological changes that 
manifest during a STEMI, ideally antiplatelet agents should be administered 
that are rapid onset of action and exhibit a uniform powerful antiplatelet effect. 
 
Study Objective  
 
To undertake a systematic review of the available evidence regarding the 
pharmacokinetic and pharmacodynamic properties of orally administered 
P2Y12 inhibitors (clopidogrel, prasugrel and ticagrelor) during the acute phase 
of a STEMI. 
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Methods 
 
Our systematic review was registered with the International Prospective 
Register of Systematic Reviews (PROSPERO) on June 19th 2015 in 
accordance with the recommendations stipulated within the PRISMA-P 
guidelines and was last updated on September 6th 2015 (CRD 42015023393) 
(28, 29)  
 
Search Strategy 
 
An initial literature search was undertaken to determine whether this research 
question has already been addressed.  At the time there were no indications 
that a review of this nature had already been completed.  The main reviewer 
(NK) and secondary reviewer (AC) agreed the systematic review question, 
search terms, search strategy and inclusion/exclusion criteria for the final 
studies to be included. A structured and comprehensive literature search was 
performed in January 2015 using Pubmed (from inception to January 2016) 
and EMBASE (Ovid) (from 1974 to December week 3 2015).  In addition, a 
search of the Cochrane database of systematic reviews was also undertaken, 
however, this did not reveal any relevant or related review topics. Secondary 
references found during the initial literature search were deemed to fall under 
the category of “grey” data/literature. 
 
 
Study Selection  
 
The key medical subheading search terms used during the literature search 
included, clopidogrel, prasugrel, ticagrelor, P2Y12 inhibitors, myocardial 
infarction, STEMI, gastrointestinal absorption, cardiogenic shock, 
pharmacokinetics and pharmacodynamics. 
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As shown in figure 1, a total of 5,760 papers were retrieved following the initial 
literature search using PubMed and a further 4,065 from EMBASE.  The 
search results were exported to a reference manager programme (EndNote) 
where duplicate searches were excluded.  Of those searches that remained (n 
= 6,374), a title and abstract review was undertaken to determine whether the 
contents of the selection were in line with the inclusion and exclusion criteria 
stipulated at the outset (Appendix 1).  For the final title/abstracts selected, full 
papers were retrieved and the contents scrutinised in more detail to determine 
their relevance in relation to the research question and inclusion criteria.  Any 
discrepancies in the search results identified were discussed by NK and AC, 
compared against the inclusion/exclusion criteria and screening questions and 
a decision made as to whether the paper should be included in the final 
review.  Where a decision regarding inclusion could not be made, the opinion 
of a third reviewer JC was sought.  In order to ensure the appropriateness of 
the final selections, a number of screening questions, based on the CASP and 
SURE toolkits were devised and utilised (Appendix 2). 
 
 
Results 
 
Study Selection and Data Extraction 
 
The screening and selection criteria for the final included citations are outlined 
in figure 1. We reviewed the full text of 117 of the 6,474 records identified 
through the initial database search.  Of these, a final twelve papers fulfilled 
our criteria for inclusion in the analysis; seven relate to pharmacodynamic 
studies and four to both pharmacodynamic and pharmacokinetic studies and 
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the remainder is a pharmacokinetic study only. Table 1 provides a summary 
of the final articles selected for inclusion in the systematic review along with 
their main findings.
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Table 1: Study, patient characteristics and findings 
 
Reference Study 
type 
Population/ 
Intervention 
Comparators Main findings 
Alexopoulos 
(30) 
PD STEMI 
(n = 55) 
 
PPCI 
Prasugrel 60mg (PO) (n = 28) 
Ticagrelor 180mg (PO)  (n = 27) 
 
VerifyNow PRU at 1hr for prasugrel PRU 257 and ticagrelor PRU 231. 
(PRU ≥ 230 indicates HTPR).  There is an initial delay in antiplatelet effect; taking approx. 
2hrs to see sufficient levels of IPA (PRU <208) 
Alexopoulos 
(31) 
PK & 
PD 
STEMI 
(N = 20)  
 
PPCI 
Ticagrelor 180mg crushed tablets 
(PO) compared with 
Ticagrelor 180mg integral tablets 
(PO)  
PD:  PRU at 0.5 and 1h, lower platelet reactivity and higher % platelet inhibition observed 
following administration of crushed compared with integral ticagrelor. 
PK: Plasma exposure of both ticagrelor and its active metabolite are greater following 
administration of crushed vs integral tablets. 
Beigel (32) PD STEMI 
(n = 79) 
 
PPCI 
 
Clopidogrel 600mg (PO) (n = 49) 
Prasugrel 60mg (PO) (n = 30) 
 
At baseline, ADP induced aggregation – comparable between prasugrel and clopidogrel. 
At PPCI -  ADP induced platelet aggregation significantly less in the prasugrel group 
compared with clopidogrel group; but less than 50% of prasugrel treated patients achieve 
IPA < 70%. 
Heestermans 
(33) 
PK STEMI vs 
healthy controls 
(n = 21) 
PPCI vs no 
intervention 
 
STEMI - clopidogrel 600mg (PO) 
(n = 11) 
Healthy controls - clopidogrel 
600mg (PO) (n = 10) 
Plasma concentration of the active thiol metabolite of clopidogrel is significantly lower in 
STEMI patients compared to the healthy controls.   
Impaired bioavailability of clopidogrel in STEMI patients leads to suboptimal levels of IPA. 
Hobl (34) PK & 
PD 
Healthy subjects  
(n =  24) 
 
No intervention 
Clopidogrel 600mg (PO) + 
morphine 5mg (IV) 
Compared with clopidogrel 600mg 
(PO) + placebo (IV) 
 
PD: morphine administration is associated with a 2hr delay in achieving maximal IPA 
PK: morphine administration significantly reduces the maximal concentration on the active 
thiol metabolite (Cmax) and prolongs the time taken to reach maximal concentration (Tmax) 
A clinically significant drug/drug interaction is apparent following the co-administration of 
morphine and clopidogrel. 
Hobl  (35) PK & 
PD 
Healthy 
(n = 12) 
 
No intervention 
Prasugrel 60mg (PO) + morphine 
5mg (IV) compared with prasugrel 
60mg (PO) + Placebo (IV) 
PD:  In healthy volunteers, the administration of morphine does not affect levels of IPA 
PK: although morphine administration reduces the maximal plasma concentration of 
prasugrel AM (Cmax), it does not have any effect on total exposure (AUC) or the time taken 
to achieve maximum concentrations (Tmax). 
Kubica  (36) PK & 
PD 
STEMI (n = 45) 
NSTEMI (n = 
15) 
 
PCI 
Ticagrelor 180mg (PO) + 
morphine 5mg (IV) compared with 
Ticagrelor 180mg (PO) + placebo 
(IV) 
 
PD: co-administration of morphine leads to an impaired antiplatelet effect as demonstrated 
by an increase in platelet reactivity compared to those patients administered placebo. 
PK: co-administration of morphine leads to a reduction in total exposure to ticagrelor and its 
active metabolite (reduced AUC and Tmax) and a reduced Cmax (maximal plasma 
concentration) 
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Orban (37) PD STEMI, 
complicated by 
cardiogenic 
shock (n = 145) 
PPCI 
Clopidogrel 600mg (PO)  
(n = 95) 
Prasugrel 60mg (PO) (n = 50) 
 
42% of patients showed HTPR following loading doses of either clopidogrel or prasugrel.  
All-cause mortality lower at 30 days in patients treated with prasugrel without any increase 
in bleeding risk. 
Osmancik (38) PD Critically ill 
STEMI   
(n = 40) 
 
PPCI 
Clopidogrel 600mg (PO) unstable 
STEMI (n=20) 
Clopidogrel 600mg (PO) stable 
STEMI (n=20) 
 
PRI >53% is indicative of clopidogrel unresponsiveness.  A greater reduction in %PRI was 
observed in stable compared to unstable STEMI patients. 
Parodi (39) PD STEMI 
(n =  50) 
 
PPCI 
Prasugrel 60mg (PO) (n = 25) 
Ticagrelor 180mg (PO) (n = 25) 
 
Only 50% of patients demonstrate effective levels of IPA at 2hrs and at least 4 hrs is 
required to see sufficient IPA in the majority of patients. 
The administration of morphine is an independent predictor of HRPR at 2 hrs 
Parodi (40) PD STEMI 
(n = 300) 
 
PPCI 
Prasugrel 60mg (PO) +/- 
morphine  (n = 95)  
Ticagrelor 180mg (PO) +/- 
morphine (n = 205) 
 
The administration of morphine is associated with delayed onset of action and HRPR for 
both prasugrel and ticagrelor. 
Parodi   (41) PD STEMI 
(N = 82) 
 
PPCI 
Ticagrelor 180mg crushed (PO) 
compared with Ticagrelor 180mg 
integral (PO) 
 
At 1h, PRU 162 for crushed ticagrelor compared with PRU 252 for integral ticagrelor with 
no difference at 2h. 
AMI – acute myocardial infarction, DTB –door to balloon time, PPCI - primary percutaneous coronary intervention, PD – pharmacodynamics PK 
– pharmacokinetic UFH – unfractionated heparin GPI – Glycoprotein IIb/IIIa inhibitor PRU – P2Y12 reactivity units PRI – platelet reactivity index 
IPA – inhibition of platelet activity HTPR – high on treatment platelet reactivity LTA – light transmission aggregometry LCMS – liquid 
chromatography tandem mass spectrometry
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Discussion 
Figure 1: PRISMA-P Flowchart/Study Selection 
Process 
Full reports/papers retrieved of relevant 
titles/abstracts for further scrutiny and 
detailed assessment against inclusion 
criteria. 
(n = 117) 
Studies included in the final 
analysis 
(n = 12) 
Full reports/papers excluded (n =105) 
Reasons: 
Platelet reactivity was not assessed during the 
desired time period (n = 15) 
Platelet reactivity was not assessed (n = 1) 
Article contents does not meet inclusion 
criteria (n = 53) 
Narrative review only (n = 16) 
Abstracts only (n = 17) 
Case report only (n = 1) 
Animal study (n = 2) 
Potentially relevant titles and abstracts 
retrieved for inspection against the 
prespecified inclusion/exclusion criteria 
(n = 6,375) 
 
Records excluded  
(n = 6,258) 
Literature search using key terms search 
terms and boolean operators 
Pubmed (n = 5,760) 
EMBASE (n = 4,065) 
Cochrane Database (n = 0) 
Exclusion of duplicates 
(n = 3,450) 
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Although the place in therapy and longer-term benefits of DAPT are well 
established, there are very little data regarding the clinical utility oral P2Y12 
inhibitors during the acute phase of a STEMI. Our systematic review 
highlights that the evidence base regarding the use of oral antiplatelet agents 
in this context is evolving as demonstrated by a number of trials that have 
been designed to assess the speed of onset, degree of platelet inhibition and 
clinical efficacy of the currently available oral P2Y12 inhibitors during the 
narrow door to balloon times that are necessary for PPCI. 
 
The pharmacodynamic and pharmacokinetic data collated and scrunitised 
during this review demonstrates inadequate levels of platelet inhibition in the 
first few hours after presentation in STEMI patients.   
 
 
Phamacodynamic Studies 
 
The pharmacodynamic studies included compare the administration of 
clopidogrel, prasugrel or ticagrelor in various patient populations; healthy 
volunteers, STEMI patients who were haemodynamically stable and unstable, 
or STEMI complicated by cardiogenic shock.   A number of platelet function 
assays were utilised and the time points at which samples were collected in 
relation to the administration of the loading doses were variable. Irrespective 
of the differences in study designs, drugs administered and platelet function 
assays used, a number of key themes are apparent.  
 
Firstly, despite the administration of prasugrel or ticagrelor loading doses, 
there is an initial delay in their onset of action, with an increase intrinsic 
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platelet reactivity present at 2 hours as demonstrated by PRU ≥ 230, 
indicating that neither agent has a particularly potent antiplatelet effect at the 
time of PPCI (30, 39)  
 
STEMI is a highly pro-thrombotic state, in which vulnerable plaque rupture 
and the subsequent endovascular injury that ensues stimulates an increase in 
platelet reactivity even prior to antiplatelet therapy. Once treated with an 
antiplatelet agent, a poor response is referred to as high residual platelet 
reactivity (HRPR) and has been shown in a number of studies to be 
associated with poor outcomes following percutaneous intervention (9, 42).  
 
Secondly, STEMI is a clinical state, which is often accompanied by 
haemodynamic instability and complications such as cardiogenic shock, the 
administration of catecholamines, systemic vasoconstriction, adrenergic 
activation and shunting of blood flow away from non-essential organs.  This 
leads to reduced perfusion of the gut and liver with subsequent impairment of 
gastrointestinal absorption and metabolic biotransformation of orally 
administered drugs into their pharmacologically active forms.  The impact of 
such physiological changes on the pharmacological effect of the oral P2Y12 
inhibitors has been investigated and quantified for clopidogrel and prasugrel, 
with both agents being subject to HRPR (37-39, 43).  
 
In the context of STEMI, all three agents (clopidogrel, prasugrel and 
ticagrelor) demonstrate significant variability in their onset of action and 
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degree to which they exert their therapeutic effect as demonstrated by the 
variable IPA results reported. 
Our review highlights that the concept of interindividual variability to response 
is not a limitation that is unique to clopidogrel only, but is also manifest with 
prasugrel and ticagrelor, albeit to a lesser extent.  With the platelet response 
to both prasugrel and ticagrelor being highly variable at the time of PPCI, 
suggesting that this interindividual variability is affected by impaired 
gastrointestinal absorption and additionally for prasugrel a subsequent 
reduction in metabolic conversion (via the liver) to its active metabolite (44). 
 
Thirdly, the co-administration of morphine introduces a clinically significant 
drug-drug interaction, which leads to a delay in the onset of action of all three 
agents, with a consequent reduction in IPA and corresponding HRPR (40).  
 
Lastly, recent trial data has demonstrated that modifying the formulation of 
ticagrelor administered to STEMI patients provides earlier and more 
pronounced levels of platelet inhibition (31, 41).  The administration of 
crushed tablets dispersed in water (unlicensed use) rather than intact film 
coated tablets allows for faster and enhanced drug absorption, particularly in 
the first hour following administration and results in higher plasma levels of 
ticagrelor and its active metabolite and consequently greater reduction in 
platelet reactivity (31, 41).   While modification of the dosage form represents 
an unlicensed, off-label use of ticagrelor, administration in such a manner 
often occurs as part of our routine clinical practice, for example in patients 
who are unconscious and/or intubated. The works of Alexopoulos and Parodi 
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provide some reassurance and demonstrate that crushing oral antiplatelets 
does not compromise their efficacy or lead to an increase in adverse effects 
e.g. stent thrombosis (31, 41).  
 
Pharmacokinetic Studies 
 
Only one study reports on pharmacokinetic data in the form of clopidogrel 
active metabolite generation in the context of STEMI; there are no data for 
prasugrel or ticagrelor active metabolite generation in this setting. 
 
The work of Heestermans et al (2008), which focuses on clopidogrel 
pharmacokinetics, provides some insights into and quantifies the altered drug 
handling that occurs secondary to a STEMI.  Generation of the clopidogrel 
active metabolite was shown to be significantly reduced in STEMI patients 
when compared to healthy controls.  The consequent reduction in 
bioavailability and platelet inhibition is thought to be secondary to impaired GI 
absorption (33). 
 
Although not undertaken in STEMI patients, the work of Hobl et al (34, 35) 
has been included in this systematic review, since both studies investigate the 
extent of the morphine-antiplatelet drug interaction in healthy patients.  Hobl’s 
work demonstrates that the co-administration of morphine leads to a reduction 
in clopidogrel active metabolite generation, demonstrated by a delay in the 
time take to achieve maximum concentration (Tmax), decrease in maximum 
concentration (Cmax) and a 34% reduction in area under the curve (AUC).  
Consequently, a decrease in antiplatelet effect is seen as demonstrated by a 
PRI >50% (34).  In contrast, although the co-administration of morphine and 
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prasugrel in healthy volunteers resulted in a 31% reduction in prasugrel active 
metaboltite generation, there was no overall observed reduction in the degree 
of platelet inhibition achieved (35).  It should be noted, however, that these 
results reflect the co-administration of morphine and prasugrel in healthy 
subjects; in the context of STEMI a reduction in antiplatelet effect in the first 
two hours after administration is likely (40, 45). 
 
Opioid based analgesia and antiplatelet drug interaction 
 
A growing body of evidence demonstrates that the administration of morphine 
inhibits peristalsis of the gut which delays gastric emptying as shown by a 
reduction in IPA (PRU >230 and %PRI >50%) as demonstrated in the studies 
included in this systematic review. 
 
The deleterious effects of opioid administration on gastric absorption on the 
background of the physiological changes that occur during a STEMI have 
been discussed from as early as the 1980’s.  Kumana et al, very eloquently 
summarised that the absorption and subsequent pharmacological handling of 
orally administered drugs is altered and impaired during an acute MI. 
Pharmacokinetic and pharmacodynamic profiles are altered secondary 
gastrointestinal hypoperfusion, the presence of nausea and vomiting and the 
administration of opioid based analgesia such as morphine that can 
predispose to gastric stasis (46)  This concept is further supported by 
Heestermans who demonstrated that physiological state of STEMI adversely 
influences intestinal absorption of orally administered clopidogrel (33).  The 
speed of onset of both prasugrel and ticagrelor in the context of STEMI is also 
delayed, with recent data demonstrating that effective levels of platelet 
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inhibition are not seen for at least 2 to 4 hours following the administration oral 
loading doses (36, 39, 45) 
 
The importance of gastric emptying as a predictor of pharmacological efficacy 
and subsequent clinical outcomes is demonstrated by the reduction in IPA, 
presence of HRPR and increased PRU as seen in the pharmacodynamic 
studies included in this review.  Morphine administration is an important 
contributing factor in the delays seen in achieving maximal levels of IPA.  For 
example, the adverse impact of morphine on ticagrelor pharmacodynamics 
was also highlighted during the ATLANTIC study.  Although a directly acting 
agent that does not require metabolic activation, the co-administration 
morphine in the ambulance leads to a delay in the onset of action of ticagrelor 
(47). Thereby indicating that ticagrelor is still reliant on gastric absorption in 
order to exert its therapeutic effect.   
 
As such, this review questions the administration of opioid based analgesia in 
the context of ACS in general, since its use has previously been associated 
with increased mortality in NSTEMI patients (48) and more recently a delay in 
the onset of action for clopidogrel, prasugrel and ticagrelor when administered 
to patients in the setting of STEMI (33, 36, 40, 49). 
 
 
 
 
 
 
Alternative Treatment Options – Antiplatelet Therapy 
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In summary, despite administration of clopidogrel, prasugrel and ticagrelor 
loading doses, a significant proportion of patients undergoing PPCI do not 
achieve optimal levels of platelet inhibition.  Gastrointestinal and hepatic 
hypoperfusion lead to impaired gastrointestinal absorption and subsequent 
metabolic conversion of clopidogrel and prasugrel.  Ticagrelor, a directly 
acting agent that does not require metabolic conversion to its active form, is 
dependent on GI absorption and as such will also be subject to a delayed 
onset of action in STEMI patients.   Consequently, all three agents display 
sup-optimal levels of IPA in the context of STEMI patients who undergo PPCI. 
 
In the highly prothrombotic state encountered in the setting of STEMI, more 
rapid and profound platelet inhibition, as achieved by intravenous agents such 
as cangrelor, may be advantageous in patients undergoing PPCI.  
Intravenous cangrelor offers the ability to achieve optimal levels of IPA in the 
narrow door to balloon time window, while the ability to transition to oral 
prasugrel/ticagrelor will allow for the longer-term benefits that are derived from 
DAPT (50).  Cangrelor also has a rapid offset of action, which may be of value 
in certain patient subsets, for example those undergoing surgery or with 
bleeding complications (51).   
While there are no head to head trials comparing the effectiveness of 
intravenous cangrelor with intravenous GPIs (abciximab, eptifibatide, 
tirofiban), both have proven efficacy in achieving rapid, high levels of platelet 
inhibition.  
Previous guideline recommendations for the use of GPIs are based on data 
derived from clinical trials that precede recent pharmacological advances in 
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oral antiplatelet therapies.  A number of studies have questioned the co-
administration of GPIs in combination with the more potent oral antiplatelet 
agents, prasugrel and ticagrelor, particularly in view of the additional bleeding 
complications that can arise following such a combination (52, 53).   A number 
of large-scale clinical trials have failed to demonstrate a significant clinical 
benefit following the administration to GPI +/- UFH in STEMI patients, such 
that even international guideline recommendations are unable to provide 
definitive endorsements regarding the utility of GPI in the era of potent oral 
P2Y12 inhibitors (11, 52, 54).  
 
 
Alternative Treatment Options – Analgesia 
While there is little evidence base to support the use of intravenous 
paracetamol in ACS patients, it does have a place in other cardiac settings 
e.g. post cardiac surgery, post-transcatheter aortic valve implantation and 
during renal denervation procedures and has been shown to have 
comparable efficacy to intravenous morphine in some settings (55-57). 
Further research is required to evaluate other analgesic agents, such as 
IV/PR paracetamol or parenteral non-steroidal anti-inflammatory drugs 
(NSAIDs) in the setting of STEMI. 
 
Limitations 
 
In common with all systematic reviews, this analysis is limited by the amount 
of currently available clinical data. We have included studies of 
heterogeneous endpoints and subject characteristics, in order to find a 
meaningful sample. 
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In addition, the timing of maximal IPA in relation to administration of the 
loading dose is not always clear and the use of background antithrombotic 
therapy between the different studies was markedly different.  The reporting of 
clinical outcomes, pharmacodynamic and pharmacokinetic data is variable 
and the impact this may have on patient outcomes is not clear.  Lastly, the 
studies included are not adequately powered to make inferences with regards 
to clinical outcomes, but they do provide further insights into, and support 
emerging evidence, indicating that even the newer generation oral P2Y12 
inhibitors are not effective in the setting of STEMI when compared to normal 
controls. 
 
Conclusion 
 
The narrow time frames from symptom onset and subsequent mechanical 
reperfusion coupled with the pathophysiological changes that occur during a 
STEMI impose immediate barriers that significantly limit the clinical utility of 
orally administered P2Y12 inhibitors in patients who present following a 
STEMI. 
The outcomes of this systematic review highlight that even though newer 
agents such as prasugrel and ticagrelor allow for greater and more consistent 
levels of inhibition of platelet activity, in the setting of STEMI, they still do not 
achieve adequate or effective levels of platelet inhibition at the time of 
mechanical reperfusion (angioplasty).  An alternative treatment option such as 
intravenous cangrelor provides an important step forward in the attempt to 
overcome the variability in response seen with all three currently available 
orally administered P2Y12 inhibitors.  In addition, the possible administration 
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of intravenous paracetamol as an alternative form of analgesia may well prove 
to be an avenue of investigation in future studies. 
 
 
Key messages 
 
- Despite providing faster, greater and more consistent inhibition of 
platelet activity (IPA), prasugrel and ticagrelor in the setting of STEMI 
are still subject to HRPR and take at least 2 to 4 hours to achieve 
effective levels of platelet inhibition. 
- The administration of morphine impairs gastrointestinal absorption of 
all three orally administered P2Y12 inhibitors with a consequent delay 
in their activity as demonstrated by a reduction in active metabolite 
generation and increased PRU and %PRI values following their co-
administration. 
- It is possible that modifying the formulation of currently available 
P2Y12 agents will lead to earlier onset and higher levels of platelet 
inhibition in the context of STEMI. However, it should be noted that a 
change in formulation is considered to be off-label use. 
 
Addendum 
 
All authors have actively contributed to the manuscript as follows: 
N. Khan, A. Cox and J Cotton were responsible for the conception, design, data 
abstraction and the analysis and interpretation of data.  N. Khan and J Cotton were 
responsible for the critical appraisal and review of data collated and manuscript 
writing. J Cotton gave final approval. 
 
Appendix 1 Systematic Review - Inclusion and Exclusion Criteria 
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 Inclusion Criteria  Exclusion Criteria  
Populations PD/PK human studies (Phase 
II, Phase III or dose finding 
studies) 
 PD/PK animal studies  
Adults > 18 years  Children < 18 years  
Adults < 70 years  Adults > 70 years 
(co-morbidities make DAPT 
difficult) 
 
Patients diagnosed 
with/recruited following an MI 
- STEMI 
- NSTEMI 
 Primary prevention or other non-
cardiac disease states 
 
Patients with unstable angina  Patients with chronic stable 
angina (stable coronary artery 
disease) 
 
Those who undergo elective PCI  
Those who are medically 
managed 
 
Doesn’t relate to inclusion criteria  
Interventions Primary PCI  Thrombolysis  
Antiplatelets -  Oral P2Y12 
inhibitors: 
Clopidogrel, Prasugrel, 
Ticagrelor 
Plavix, Efient, Brilique 
 
Pre-procedural loading 
 
Intravenous antiplatelet 
agents: 
Cangrelor, eptifibatide, 
abciximab, tirofiban 
 
 Oral antiplatelets: 
Cilostazol, dipyridamole, 
ticlodipine 
 
Oral P2Y12 inhibitor 
(clopidogrel/prasugrel/ticagrelor) 
loading post-PCI 
 
 
 
 
Other medications 
administered at the time of 
PCI – morphine/diamorphine 
 
Comparators STEMI vs NSTEMI  Doesn’t relate to inclusion criteria 
 
Papers on HTPR with clopidogrel 
and clopidogrel 
pharmacogenomics. 
 
Drug handling - ADME  
Degree of IPA STEMI vs 
NSTEMI vs healthy volunteer 
 
Clopidogrel, prasugrel, 
ticagrelor, cangrelor 
 
In extremis vs healthy  
Outcomes %IPA    
 PRI    
 PRU    
 Adverse events (relate back 
to question) 
   
 Mortality (relate back to 
question) 
   
 Bleeding complications 
(relate back to question) 
   
Study Design RCTs  Abstracts  
 Comparative studies  Case reports  
 Placebo controlled studies    
 English only papers    
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Appendix 2 -  Screening questions to assess the quality and 
appropriateness of the final articles selected for scrutiny prior to 
inclusion in the systematic review. 
 
 Yes Unclear No 
1. Does the study/paper relate back to the research 
question? 
(Is there a clear statement of the aims of the 
research/paper?) 
   
Population/problem?    
Intervention?    
Comparator/control?    
Outcomes? (is primary outcome identified?)    
RCT    
2. Was the population randomised? If yes, were the 
methods appropriate? 
   
Was allocation to a comparator/group concealed?    
Were the participants/investigators blinded to group 
allocation? 
   
Were interventions/comparators well described and 
appropriate? 
   
Were the groups similar at the start of the trial?    
Was the sample size sufficient?    
Were participants appropriately accounted for?    
Data analysis – appropriate?    
Results – were outcomes measures reliable and 
complete? 
   
Qualitative    
3. Was the qualitative methodology appropriate?    
4. Was the research strategy appropriate to the aims of 
the research? 
   
5. Was the recruitment strategy appropriate to the aims 
of the research? 
   
6. Was the data collected in a way that addressed the 
research issue? 
   
7. Have ethical issues been taken into consideration?    
8. Was the data analysis sufficiently rigorous?    
9. Is there a clear statement of findings?    
10. Are there any major limitations?    
11. How well does the paper/research relate back to your 
research question? 
 
 
 Yes/No Explanation 
Include   
 
 
 
 
Exclude   
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Appendix 3 – Supplementary data – Comprehensive overview of the final 
studies selected for inclusion in the systematic review detailing study design, 
patient populations, interventions and drug therapies administered in addition 
to main trial outcomes. 
 
 
Reference Alexopoulos (30) 
Study type Pharmacodynamic 
Population STEMI  (n = 55) 
Intervention PPCI 
Comparators Prasugrel 60mg (PO) (n = 28) 
Ticagrelor 180mg (PO)  (n = 27) 
Background 
antithrombotic therapy 
Unspecified 
Platelet function 
tests/Analysis undertaken 
VerifyNow and Multiplate Analyser samples taken at 
baseline, 1,2,6, 24 hours and 5 days post loading 
Findings VerifyNow results demonstrate that PRU at 1hr 
prasugrel 257 and ticagrelor 231. 
(PRU ≥ 230 indicates HTPR).  There is an initial delay in 
antiplatelet effect; taking approx. 2hrs to see sufficient 
levels of IPA (PRU <208) 
 
 
Reference Alexopoulos  (31) 
Study type Pharmacokinetic and pharmacodynamic 
Population STEMI  (n = 20) 
Intervention PPCI 
Comparators Ticagrelor 180mg crushed tablets (PO) compared with 
Ticagrelor 180mg integral tablets (PO) 
Background 
antithrombotic therapy 
Aspirin 325mg (PO) 
UFH 70U/kg +/- bivalirudin 
Platelet function 
tests/Analysis undertaken 
PD assessment:  VerifyNow 
PK assessment: LC/MS 
Samples collected for analysis at baseline, 0.5h, 1h, 2h 
and 4h 
Findings PD:  PRU at 0.5 and 1h, lower platelet reactivity and 
higher % platelet inhibition observed following 
administration of crushed compared with integral 
ticagrelor. 
PK: Plasma exposure of both ticagrelor and its active 
metabolite are greater following administration of 
crushed vs integral tablets. 
 
 
Reference Beigel (32) 
Study type Pharmacodynamic 
Population STEMI (n = 79) 
Intervention PPCI 
Comparators Clopidogrel 600mg (PO) (n = 49) 
Prasugrel 60mg (PO) (n = 30) 
Background 
antithrombotic therapy 
Aspirin 100mg (PO) +/- GPI (tirofiban) 
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Platelet function 
tests/Analysis undertaken 
LTA at baseline, at PPCI and after 72hrs 
Findings Mean DTB – 48 +/-20 mins 
At baseline, ADP induced aggregation – comparable 
between prasugrel and clopidogrel. 
At PPCI - ADP induced platelet aggregation significantly 
less in the prasugrel group compared with clopidogrel 
group; but less than 50% of prasugrel treated patients 
achieve IPA <70%. 
 
 
Reference Heestermans (33) 
Study type Pharmacokinetic 
Population STEMI vs healthy controls 
(n = 21) 
Intervention PPCI 
Comparators STEMI - clopidogrel 600mg (PO) (n = 11) 
Healthy controls - clopidogrel 600mg (PO) (n = 10) 
Background 
antithrombotic therapy 
Aspirin 900mg (IV) + UFH 70IU/kg 
Platelet function 
tests/Analysis undertaken 
LCMS pre-dose, 0.5hrs, 1hrs, 1.5hrs, 2hrs, 3hrs, 4hrs, 
6hrs and 24 hrs post-loading 
Findings Plasma concentration of the active thiol metabolite of 
clopidogrel is significantly lower in STEMI patients 
compared to the healthy controls.   
Impaired bioavailabilty of clopidogrel in STEMI patients 
leads to suboptimal levels of IPA. 
 
Reference Hobl (34) 
Study type Pharmacokinetic and Pharmacodynamic 
Population Healthy subjects (n = 24) 
Intervention None 
Comparators Clopidogrel 600mg (PO) + morphine 5mg (IV) 
compared with Clopidogrel 600mg (PO) + placebo (IV) 
Background 
antithrombotic therapy 
None administered 
Platelet function 
tests/Analysis undertaken 
PD assessment: VASP phosphorylation assay 
PK assessment: LC/MS 
Findings PD: morphine administration is associated with a 2hr 
delay in achieving maximal IPA 
PK: morphine administration significantly reduces the 
maximal concentration on the active thiol metabolite 
(Cmax) and prolongs the time taken to reach maximal 
concentration (Tmax) 
A clinically significant drug/drug interaction is apparent 
following the co-administration of morphine and 
clopidogrel. 
 
 
 
Reference Hobl (35) 
Study type Pharmacokinetic and Pharmacodynamic 
Population Healthy (n = 12) 
Intervention None 
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Comparators Prasugrel 60mg (PO) + morphine 5mg (IV) compared 
with Prasugrel 60mg (PO) + Placebo (IV) 
Background 
antithrombotic therapy 
None administered 
Platelet function 
tests/Analysis undertaken 
PD assessment: VASP phosphorylation assay and 
Multiplate Analyser 
PK assessment:  LC/MS 
Findings PD:  In healthy volunteers, the administration of 
morphine does not affect levels of IPA 
PK: although morphine administration reduces the 
maximal plasma concentration of prasugrel AM (Cmax), 
it does not have any effect on total exposure (AUC) or 
the time taken to achieve maximum concentrations 
(Tmax). 
 
 
Reference Kubica (35) 
Study type Pharmacokinetic and Pharmacodynamic 
Population ACS (STEMI = 45  and NSTEMI = 15) 
Intervention Ticagrelor 180mg (PO) + morphine 5mg (IV) compared 
with ticagrelor 180mg (PO) + placebo (IV) 
Comparators  
Background 
antithrombotic therapy 
Aspirin 300mg (PO) +/- GPI 
Platelet function 
tests/Analysis undertaken 
PD: VASP phosphorylation assay, Multiplate Analyser, 
VerifyNow 
PK: LC-MS/MS 
Samples taken at baseline, 0.5h, 1h, 2h, 3h, 4h, 6h and 
12h 
Findings PD: co-administration of morphine leads to an impaired 
antiplatelet effect as demonstrated by an increase in 
platelet reactivity compared to those patients 
administered placebo. 
PK: co-administration of morphine leads to a reduction 
in total exposure to ticagrelor and its active metabolite 
(reduced AUC and Tmax) and a reduced Cmax 
(maximal plasma concentration) 
 
 
Reference Orban (37 
Study type Pharmacodynamic 
Population STEMI (complicated by cardiogenic shock) (n = 145) 
Intervention PPCI 
Comparators Clopidogrel 600mg (PO)  
(n = 95) 
Prasugrel 60mg (PO) (n = 50) 
Background 
antithrombotic therapy 
Aspirin 500mg (IV) + UFH 5,000IU 
Platelet function 
tests/Analysis undertaken 
Multiplate Analyser 
Findings 42% of patients showed HTPR following loading doses 
of either clopidogrel or prasugrel.  All-cause mortality 
lower at 30 days in patients treated with prasugrel 
without any increase in bleeding risk. 
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Reference Osmancik (38) 
Study type Pharmacodynamic 
Population Critically ill STEMI  (n = 40) 
Intervention PPCI 
Comparators Clopidogrel 600mg (PO) unstable STEMI (n=20) 
Clopidogrel 600mg (PO) stable STEMI (n=20) 
Background 
antithrombotic therapy 
Aspirin 500mg (IV) + UFH 150IU/kg +/- GPI 
Platelet function 
tests/Analysis undertaken 
VASP phosphorylation assay at baseline, 4, 24 and 48 
hrs post clopidogrel loading 
Findings PRI >53% is indicative of clopidogrel unresponsiveness.  
A greater reduction in %PRI was observed in stable 
compared to unstable STEMI patients. 
 
 
Reference Parodi (35) 
Study type Pharmacodynamic 
Population STEMI (n = 50) 
Intervention PPCI 
Comparators Prasugrel 60mg (PO) (n = 25) 
Ticagrelor 180mg (PO) (n = 25) 
Background 
antithrombotic therapy 
Aspirin 500mg (IV) + bivalirudin only 
Platelet function 
tests/Analysis undertaken 
VerifyNow at baseline, 2,4,8 and 12hrs post loading 
Findings Only 50% of patients demonstrate effective levels of IPA 
at 2hrs and at least 4 hrs is required to see sufficient 
IPA in the majority of patients. 
The administration of morphine is an independent 
predictor of HRPR at 2 hrs 
 
 
Reference Parodi (40) 
Study type Pharmacodynamic 
Population STEMI (n =  300) 
Intervention PPCI 
Comparators Prasugrel 60mg (PO) +/- morphine  (n = 95)  
Ticagrelor 180mg (PO) +/- morphine  (n = 205) 
Background 
antithrombotic therapy 
Aspirin 300-500mg + bivalirudin only 
Platelet function 
tests/Analysis undertaken 
VerifyNow 1,2,and 4hrs post loading 
Findings The administration of morphine is associated with 
delayed onset of action and HRPR for both prasugrel 
and ticagrelor. 
 
 
Reference Parodi (41) 
Study type Pharmacodynamic 
Population STEMI (n =  82) 
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Intervention PPCI 
Comparators Ticagrelor 180mg (PO) crushed compared with 
Ticagrelor 180mg (PO) integral 
Background 
antithrombotic therapy 
Not specified in trial protocol. 
Platelet function 
tests/Analysis undertaken 
VerifyNow at 0h, 1h, 2h, 4h and 8h 
Findings At 1 h, PRU 162 for crushed ticagrelor compared with 
PRU 252 for integral ticagrelor with no difference at 2h. 
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